The flow of science in this modern age is largely controlled by just six corporate publishing groups, which by calculated design have been gobbling up the journal market since at least the 1970s. And a new study out of Canada reveals that this mass consolidation of publishing power is, to a large extent, skewing what passes as scientific progress.
Recently in Pharma Category
CDC Scientist: ‘We scheduled meeting to destroy vaccine-autism study documents’
A current Centers for Disease Control (CDC) senior scientist has made an unprecedented admission: he and his colleagues–he says– committed scientific misconduct to cover up a meaningful link between vaccines and autism in black boys.
Just as startling, the CDC scientist, Dr. William Thompson, says the study co-authors “scheduled a meeting to destroy documents related to the study. The remaining four co-authors all met and brought a big garbage can into the meeting room, and reviewed and went through all the hardcopy documents that we had thought we should discard, and put them into a huge garbage can.”
REP. Bill Posey Calling for an Investigation of the CDC's MMR reasearch fraud
Rep. Bill Posey brings former CDC researcher and now Whistleblower, Dr. Bill Thompson's letter regarding significant files they omitted and destroyed to avoid reporting any significant race effects in their study.
Recently headlines were made as 118 oncologist, of the 22,125 currently active in the United States, sounded the alarm publicly about the rising price of cancer drugs calling them “unsustainable.” This rebellious 118, or half of one percent, appear to be making a valid argument from within a tightly controlled and highly profitable cancer industry. Perhaps unaware to most oncologist and others within the mainstream medical system is that drug companies rely on fraud and half truths to circulate their products. In fact, most major drug companies have repeatedly shown that profit margins trump empathy, true healing and human life 8 days a week.
While vaccines for mumps, rubella and measles protect those who are vaccinated and prevent them infecting others, new jabs leave a risk of infecting others
The following open letter by a PhD Immunologist completely demolishes the current California legislative initiative to remove all vaccine exemptions. That such a draconian and cynical state statute is under consideration in the ‘Golden State’ is as shocking as it is predictable. After all, it was mysteriously written and submitted shortly after the manufactured-in-Disneyland measles ‘outbreak’.
Health Impact News Editor Comments
Dr. MaryAnne Demasi’s documentary on the criminal activity of the pharmaceutical industry regarding cholesterol-lowering statin drugs sent shock waves through the mainstream media in Australia last year. Published in two parts on the popular news show The Catalyst, the pharmaceutical industry complained loudly after the first show, and requested the network not air the second episode, “Heart of the Matter Part 2 – Cholesterol Drug War.”
ABC Australia aired it anyway, but the pharmaceutical influence is apparently too strong, as it was announced that the network would remove the videos from their website because “they breached its impartiality standards.” They also removed them from YouTube.
Waning of Maternal Antibodies Against Measles, Mumps, Rubella, and Varicella in Communities With Contrasting Vaccination CoverageSandra Waaijenborg1,3, Susan J. M. Hahné1, Liesbeth Mollema1, Gaby P. Smits2, Guy A. M. Berbers2, Fiona R. M. van der Klis2, Hester E. de Melker1, Jacco Wallinga1
Correspondence: Sandra Waaijenborg, PhD, National Institute of Public Health and the Environment, Centre for Infectious Disease Control, Epidemiology and Surveillance Unit, PO Box 1, 3720 BA Bilthoven, the Netherlands (email@example.com).
Presented in part: European Society for Pediatric Infectious Diseases, The Hague, the Netherlands (poster) June 2011. Partly presented as a poster at the Nordic Vaccine meeting, Copenhagen, 5–7 September 2012.
The global market for cancer drugs has hit $100 billion in annual sales, and could reach $147 billion by 2018, according to a new report by the IMS Institute for Healthcare Informatics, a unit of drug data provider IMS Health.
This figure does not include discounts or rebates paid to insurers and government programs; IMS says that in the case of cancer drugs, this should not make a big difference the overall figure.